Trials Sponsors Conditions Drugs Pricing

Conditions

Hypertension

Outcome Measures

Primary Outcomes (1)

Relative hazard of composite outcome of Heart Failure, Stroke, MI, and Mortality
Relative hazard of composite outcome of Heart Failure, Stroke, MI, and Mortality - Please refer to uploaded protocol for full definition due to size limitations.
[Time Frame: Through study completion (a median of ***118-123**** days)]

Study Arms (2)

Ramipril

Reference group

Drug: Ramipril

Telmisartan

Exposure group

Drug: Telmisartan

Interventions

RamiprilDrug

Ramipril dispensing claim is used as the reference

Ramipril

TelmisartanDrug

Telmisartan dispensing claim is used as the exposure

Telmisartan

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age55 Years+

Sexall

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

This study will involve a new user, parallel group, cohort study design comparing telmisartan to ramipril. The patients will be required to have continuous enrollment during baseline period of 180 days before initiation of telmisartan or the comparator drug (cohort entry date). Follow-up for the outcome, begins the day after drug initiation. As in the trial, patients are allowed to take other antihypertensive medications during the study.

You may qualify if:

Individuals 55 years of age with 1 of the following:

Sponsors & Collaborators

Brigham and Women's Hospital
Otherlead

Study Sites (1)

Brigham And Women's Hospital

Boston, Massachusetts, 02120, United States

MeSH Terms

Conditions

Hypertension

Interventions

RamiprilTelmisartan

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Heterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsBiphenyl CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, Cyclic

Study Officials

Shirley Wang, PhD, ScM
Brigham and Women's Hospital
PRINCIPAL INVESTIGATOR

Enrollment

63,744 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Associate Professor of Medicine

Study Record Dates

First Submitted

April 17, 2020

First Posted

April 21, 2020

Study Start

September 22, 2017

Actual (reported)

Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Ramipril

Telmisartan

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Documents

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Ramipril

Telmisartan

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Documents

Locations